Gottfried Schmalz1, Kerstin M Galler2. 1. Department of Conservative Dentistry, University of Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany; Department of Preventive, Restorative and Pediatric Dentistry, University of Bern, Freiburgstrasse 7, CH-3010 Bern, Switzerland. Electronic address: gottfried.schmalz@ukr.de. 2. Department of Conservative Dentistry, University of Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany.
Abstract
OBJECTIVES: Biocompatibility of dental materials has gained increasing interest during recent decades. Meanwhile, legal regulations and standard test procedures are available to evaluate biocompatibility. Herein, these developments will be exemplarily outlined and some considerations for the development of novel materials will be provided. METHODS: Different aspects including test selection, release of substances, barriers, tissue healing, antibacterial substances, nanoparticles and environmental aspects will be covered. The provided information is mainly based on a review of the relevant literature in international peer reviewed journals, on regulatory documents and on ISO standards. RESULTS: Today, a structured and systematic approach for demonstrating biocompatibility from both a scientific and regulatory point of view is based on a clinical risk assessment in an early stage of material development. This includes the analysis of eluted substances and relevant barriers like dentin or epithelium. ISO standards 14971, 10993, and 7405 specify the modes for clinical risk assessment, test selection and test performance. In contact with breached tissues, materials must not impair the healing process. Antibacterial effects should be based on timely controllable substances or on repellant surfaces. Nanoparticles are produced by intraoral grinding irrespective of the content of nanoparticles in the material, but apparently at low concentrations. Concerns regarding environmental aspects of mercury from amalgam can be met by amalgam separating devices. The status for other materials (e.g. bisphenol-A in resin composites) needs to be evaluated. Finally, the public interest for biocompatibility issues calls for a suitable strategy of risk communication. SIGNIFICANCE: A wise use of the new tools, especially the clinical risk assessment should aim at preventing the patients, professionals and the environment from harm but should not block the development of novel materials. However, biocompatibility must always be weighed against the beneficial effects of materials in curing/preventing oral diseases.
OBJECTIVES: Biocompatibility of dental materials has gained increasing interest during recent decades. Meanwhile, legal regulations and standard test procedures are available to evaluate biocompatibility. Herein, these developments will be exemplarily outlined and some considerations for the development of novel materials will be provided. METHODS: Different aspects including test selection, release of substances, barriers, tissue healing, antibacterial substances, nanoparticles and environmental aspects will be covered. The provided information is mainly based on a review of the relevant literature in international peer reviewed journals, on regulatory documents and on ISO standards. RESULTS: Today, a structured and systematic approach for demonstrating biocompatibility from both a scientific and regulatory point of view is based on a clinical risk assessment in an early stage of material development. This includes the analysis of eluted substances and relevant barriers like dentin or epithelium. ISO standards 14971, 10993, and 7405 specify the modes for clinical risk assessment, test selection and test performance. In contact with breached tissues, materials must not impair the healing process. Antibacterial effects should be based on timely controllable substances or on repellant surfaces. Nanoparticles are produced by intraoral grinding irrespective of the content of nanoparticles in the material, but apparently at low concentrations. Concerns regarding environmental aspects of mercury from amalgam can be met by amalgam separating devices. The status for other materials (e.g. bisphenol-A in resin composites) needs to be evaluated. Finally, the public interest for biocompatibility issues calls for a suitable strategy of risk communication. SIGNIFICANCE: A wise use of the new tools, especially the clinical risk assessment should aim at preventing the patients, professionals and the environment from harm but should not block the development of novel materials. However, biocompatibility must always be weighed against the beneficial effects of materials in curing/preventing oral diseases.
Authors: Cristiane Miranda França; Anthony Tahayeri; Nara Sousa Rodrigues; Shirin Ferdosian; Regina Maria Puppin Rontani; Grigoriy Sereda; Jack L Ferracane; Luiz E Bertassoni Journal: Lab Chip Date: 2019-12-19 Impact factor: 6.799
Authors: Ralf Bürgers; Andrea Schubert; Jonas Müller; Sebastian Krohn; Matthias Rödiger; Andreas Leha; Torsten Wassmann Journal: Clin Exp Dent Res Date: 2022-05-15
Authors: Hana Dvořáková; Jan Čech; Monika Stupavská; Lubomír Prokeš; Jana Jurmanová; Vilma Buršíková; Jozef Ráhel'; Pavel St'ahel Journal: Polymers (Basel) Date: 2019-10-04 Impact factor: 4.329
Authors: Adam Wawrzynkiewicz; Wioletta Rozpedek-Kaminska; Grzegorz Galita; Monika Lukomska-Szymanska; Barbara Lapinska; Jerzy Sokolowski; Ireneusz Majsterek Journal: Int J Mol Sci Date: 2020-05-31 Impact factor: 5.923